Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global Respiratory Drugs Market Briefing 2017 - Anti-Asthmatics And COPD Drugs, Cough And Cold Preparations - Research and Markets

Research and Markets
Posted on: 03 Jan 18

The "Respiratory Drugs Market Global Briefing 2017" report has been added to Research and Markets' offering.

The global respiratory drugs market is expected to reach around $65 billion in 2020. Going forward, the rise in global air pollution levels will lead to higher number of respiratory diseases thus driving the respiratory drugs market.

Respiratory diseases drugs market covers drugs that are used in the treatment of a wide range of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), chronic and acute bronchitis, emphysema and cystic fibrosis. Some of the major drugs in the market include antimuscarinics, corticosteroids, Codral, Coldrex and Lemsip. The market numbers in this briefing cover pharmaceutical (drug) treatments and do not cover biologic treatments for these conditions which are included in a separate briefing.

Growing Demand For Tamper-Resistant Pseudoephedrine (PSE) Products - The demand for PSE-containing cold, allergy, and sinus products is growing due to their effectiveness and convenience. PSE is an active ingredient found in various cold, allergy, and sinus drugs that can provide congestion relief. However, PSE-containing medicines are mostly sold as a prescription drug, as PSE can also be used for the illegal manufacture of methamphetamine, a recreational drug. This has led drug manufacturers to produce tamper-resistant PSE products.

For instance, in March 2017, pharmaceutical companies Acura Pharmaceuticals Inc. and MainPointe Pharmaceuticals LLC entered into an agreement, enabling MainPointe Pharmaceuticals LLC to market NEXAFED and NEXAFED Sinus products in the US and Canada. These drugs utilize tamper-resistant PSE formulation to prevent the illicit production of methamphetamine.


  • Markets Covered: Anti-Asthmatics And COPD Drugs, Cough And Cold Preparations.
  • Time Series: Five years historic and forecast.
  • Data: Market value in $ billions.
  • Data Segmentations: Regional breakdowns, market share of competitors, key sub segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Companies Mentioned

  • GlaxosmithKline Plc.
  • AstraZeneca Plc.
  • Merck & Co.
  • Novartis AG
  • Johnson & Johnson
  • Gilead
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Teva Pharmaceuticals
  • Pfizer Inc.

For more information about this report visit

View source version on

Business Wire

Last updated on: 03/01/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.